[Multibilly]

Interesting Revlimid maintenance study results

by Multibilly on Thu Dec 20, 2018 7:57 pm

The full article can be found here:

Jackson, GH, et al., "Lena­lido­mide main­tenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial," Lancet Oncology, Dec 14, 2018 (full text of article)

While progression-free survival improved in the overall trial population, that could not be said of overall survival when analyzed across the entire trial population. However, certain groups did benefit in overall survival in this study. Keep in mind that the study urges caution in interpreting the results since it did not utilize any power analysis techniques (i.e. the researchers did not perform an analysis on whether the population sample size used would yield reliable results).

From the article:

Interpretation - Maintenance therapy with lenalidomide [Revlimid] significantly improved progression-free survival in patients with newly diagnosed multiple myeloma compared with observation, but did not improve overall survival in the intention-to-treat analysis [a statistical analysis technique which includes every subject who is randomized according to randomized treatment assignment. It ignores noncompliance, protocol deviations, withdrawal, and anything that happens after randomization] of the whole trial population. The manageable safety profile of this drug and the encouraging results in subgroup analyses of patients across all cytogenetic risk groups support further investigation of maintenance lenalidomide in this setting.

[janimcdo]

Re: Interesting Revlimid maintenance study results

by janimcdo on Wed Jan 02, 2019 2:01 pm

Thanks for this posting.